Steven T Staben

List of Publications by Year in descending order

28 papers	1,360 citations	361413 20 h-index	501196 28 g-index
30 all docs	30 docs citations	30 times ranked	1910 citing authors

#	Article	IF	Citations
1	A Multifaceted Hit-Finding Approach Reveals Novel LC3 Family Ligands. Biochemistry, 2023, 62, 633-644.	2.5	8
2	RTK-Dependent Inducible Degradation of Mutant PI3KÎ± Drives GDC-0077 (Inavolisib) Efficacy. Cancer Discovery, 2022, 12, 204-219.	9.4	40
3	Primary Amine Tethered Small Molecules Promote the Degradation of X-Linked Inhibitor of Apoptosis Protein. Journal of the American Chemical Society, 2021, 143, 10571-10575.	13.7	7
4	Selective activation of PFKL suppresses the phagocytic oxidative burst. Cell, 2021, 184, 4480-4494.e15.	28.9	61
5	Heterobifunctional Molecules Induce Dephosphorylation of Kinasesâ€“A Proof of Concept Study. Journal of Medicinal Chemistry, 2020, 63, 2807-2813.	6.4	88
6	Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases. Journal of Medicinal Chemistry, 2020, 63, 7957-7985.	6.4	10
7	Monomeric Targeted Protein Degraders. Journal of Medicinal Chemistry, 2020, 63, 11330-11361.	6.4	48
8	Structure Based Design of Potent Selective Inhibitors of Protein Kinase D1 (PKD1). ACS Medicinal Chemistry Letters, 2019, 10, 1260-1265.	2.8	5
9	MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. PLoS Biology, 2019, 17, e3000354.	5.6	94
10	NF-ÎºB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nature Communications, 2018, 9, 179.	12.8	98
11	Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-ÎºB Inducing Kinase. Journal of Medicinal Chemistry, 2018, 61, 6801-6813.	6.4	38
12	Structure-Based Design of Tricyclic NF-ÎºB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K). Journal of Medicinal Chemistry, 2017, 60, 627-640.	6.4	51
13	Isoform Selective PI3K Inhibitors for Treating Cancer. Topics in Medicinal Chemistry, 2017, , 333-333.	0.8	2
14	Design of Selective Benzoxazepin PI3KÎ´ Inhibitors Through Control of Dihedral Angles. ACS Medicinal Chemistry Letters, 2017, 8, 936-940.	2.8	21
15	A General Strategy for the Construction of Functionalized Azaindolines via Domino Palladium-Catalyzed Heck Cyclization/Suzuki Coupling. Organic Letters, 2017, 19, 3616-3619.	4.6	45
16	Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development. Cancer Research, 2017, 77, 156-156.	0.9	11
17	The Rational Design of Selective Benzoxazepin Inhibitors of the Î±-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326). Journal of Medicinal Chemistry, 2016, 59, 985-1002.	6.4	87
18	Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 1033-1045.	6.4	50

#	Article	IF	Citations
19	Cis-Amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 897-901.	2.2	14
20	Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase Î² isoform. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2606-2613.	2.2	21
21	Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2â€“4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyr (GDC-0032): A Î²-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity. Journal of Medicinal Chemistry, 2013, 56, 4597-4610.	6.4	161
22	Potent and selective inhibitors of PI3KÎ´: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4296-4302.	2.2	48
23	The Crystal Structure of the Catalytic Domain of the NF-ÎºB Inducing Kinase Reveals a Narrow but Flexible Active Site. Structure, 2012, 20, 1704-1714.	3.3	57
24	Rational Design of Phosphoinositide 3-Kinase Î± Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase Î² Isoform. Journal of Medicinal Chemistry, 2011, 54, 7815-7833.	6.4	60
25	Rapid Synthesis of 1,3,5-Substituted 1,2,4-Triazoles from Carboxylic Acids, Amidines, and Hydrazines. Journal of Organic Chemistry, 2011, 76, 1177-1179.	3.2	91
26	Structure-based design of thienobenzoxepin inhibitors of PI3-kinase. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4054-4058.	2.2	30
27	Fourâ€Component Synthesis of Fully Substituted 1,2,4â€Triazoles. Angewandte Chemie - International Edition, 2010, 49, 325-328.	13.8	89
28	Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6048-6051.	2.2	24